SCHEMBL23218784

SCHEMBL23218784

CCOC(=O)Cc1ccccc1OCc1c(C(C)(C)C)oc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFD P00746 14/20 0.53
F11 P03951 6/20 0.49
TPSB2 P20231 5/20 0.49
KLKB1 P03952 2/20 0.49
PLAU P00749 2/20 0.49
PLG P00747 1/20 0.49
F7 P08709 1/20 0.49
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
ANO1 Q5XXA6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852498 1.00 CFD (0.53) CFDF11TPSB2KLKB1PLAU
SCHEMBL23218514 0.92 CFD (0.45) CFDF11TPSB2KLKB1PLAU
SCHEMBL29852786 0.92 CFD (0.45) CFDF11TPSB2KLKB1PLAU
SCHEMBL29852589 0.92 CFD (0.44) CFDF11TPSB2KLKB1PLAU
SCHEMBL23218703 0.92 CFD (0.44) CFDF11TPSB2KLKB1PLAU
SCHEMBL23218677 0.90 CFD (0.63) CFDF11TPSB2KLKB1PLAU
SCHEMBL29852410 0.90 CFD (0.63) CFDF11TPSB2KLKB1PLAU
SCHEMBL23218837 0.90 CFD (0.53) CFDF11TPSB2KLKB1PLAU
SCHEMBL29852712 0.90 CFD (0.53) CFDF11TPSB2KLKB1PLAU
SCHEMBL23218345 0.90 CFD (0.43) CFDF11TPSB2KLKB1PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885F11 24/4885TPSB2 419/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 14/4885TPSB2 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.